RenovoRx is a clinical-stage pharmaceutical company developing drug/device combination products for localized cancer treatment, centered on its proprietary RenovoCath intra-arterial delivery device that has received FDA clearance for standalone use. The company is commercializing RenovoCath as a medical device to hospitals and treatment centers, while advancing IAG—a combination of RenovoCath with gemcitabine chemotherapy—for locally advanced pancreatic cancer and cholangiocarcinoma, both of which have received FDA Orphan Drug Designation. Revenue currently derives from RenovoCath device sales, with future revenue potential from IAG pharmaceutical product sales and device usage if the drug/device combination receives FDA approval; the company faces typical biotech constraints including dependence on third-party manufacturers, exposure to complex healthcare regulations, and competition from larger pharmaceutical companies and emerging biotech firms developing treatments in the same oncology space.